Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A
Atassi, M.Zouhair.; Jankovic, J.; Dolimbek, B.Z.
Neurology 71(13): 1040; Author Reply 1040-1
2008
ISSN/ISBN: 0028-3878
PMID: 18809844
DOI: 10.1212/01.wnl.0000327865.05877.17
Accession: 054594346
PDF emailed within 0-6 h: $19.90
Related References
Kranz, G.; Sycha, T.; Voller, B.; Kranz, G.S.; Schnider, P.; Auff, E. 2008: Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type a Neurology 70(2): 133-136Zuber, M.; Sebald, M.; Bathien, N.; de Recondo, J.; Rondot, P. 1993: Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance Neurology 43(9): 1715-1718
Ianhez, M.; Peres, G.; Miot, H.él.A. 2021: Neutralizing Antibodies to Botulinum Toxin Type a Are Rare Following Aesthetic Indications Aesthetic Surgery Journal 41(11): Np1800-Np1801
Dressler, D.; Lange, M.; Bigalke, H. 2003: Detecting neutralizing antibodies against botulinum toxin type B with a mouse diaphragm assay Annals of Neurology 54(Suppl 7): S71
Lange, O.; Bigalke, H.; Dengler, R.; Wegner, F.; deGroot, M.; Wohlfarth, K. 2009: Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clinical Neuropharmacology 32(4): 213-218
Rollnik, J.D.; Wohlfarth, K.; Dengler, R.; Bigalke, H. 2001: Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia Neurology and Clinical Neurophysiology: Ncn 3: 2-4
Voller, B.; Moraru, E.; Auff, E.; Benesch, M.; Poewe, W.; Wissel, J.ör.; Müller, J.ör.; Entner, T.; Bigalke, H.; Schnider, P. 2004: Ninhydrin sweat test: a simple method for detecting antibodies neutralizing botulinum toxin type a Movement Disorders: Official Journal of the Movement Disorder Society 19(8): 943-947
Yablon, S.A.; Brashear, A.; Gordon, M.F.; Elovic, E.P.; Turkel, C.C.; Daggett, S.; Liu, J.; Brin, M.F. 2007: Formation of neutralizing antibodies in patients receiving botulinum toxin type a for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials Clinical Therapeutics 29(4): 683-690
Wu, H.C.; Yeh, C.T.; Huang, Y.L.; Tarn, L.J.; Lung, C.C. 2001: Characterization of neutralizing antibodies and identification of neutralizing epitope mimics on the Clostridium botulinum neurotoxin type A Applied and Environmental Microbiology 67(7): 3201-3207
Paus, S.; Bigalke, H.; Klockgether, T. 2006: Neutralizing antibodies against botulinum toxin a after a wasp sting Archives of Neurology 63(12): 1808-1809
Siegel, L.S. 1989: Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid Journal of Clinical Microbiology 27(8): 1906-1908
Birklein, F.; Walther, D.; Bigalke, H.; Winterholler, M.; Erbguth, F. 2002: Sudomotor testing predicts the presence of neutralizing botulinum a toxin antibodies Annals of Neurology 52(1): 68-73
Rasetti-Escargueil, C.; Avril, A.; Chahboun, S.; Tierney, R.; Bak, N.; Miethe, S.; Mazuet, C.; Popoff, M.R.; Thullier, P.; Hust, M.; Pelat, T.; Sesardic, D. 2015: Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B Mabs 7(6): 1161-1177
Göschel, H.; Wohlfarth, K.; Frevert, J.; Dengler, R.; Bigalke, H. 1997: Botulinum a toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences Experimental Neurology 147(1): 96-102
Arnon, S.; Maslanka, S.; Schechter, R.; Hatheway, C. 2002: Development of neutralizing serum antibodies to botulinum toxin in patients with infant botulism Naunyn-Schmiedeberg's Archives of Pharmacology 365(Suppl 2): R11
Duane, D.D.; Monroe, J.; Morris, R.E. 2000: Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia Movement Disorders: Official Journal of the Movement Disorder Society 15(2): 365-366
Anis, O.; Gilburd, B.; Kitrey, N.D. 2021: Test for Neutralizing Antibodies in Urologic Patients with no Response to Intravesical Botulinum Toxin Injections Harefuah 160(6): 382-385
Aoki, K.R.; Spanoyannis, A.F. 2000: Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample Official Gazette of the United States Patent and Trademark Office Patents 1239(4)
Torii, Y.; Takahashi, M.; Ishida, S.; Goto, Y.; Nakahira, S.; Harakawa, T.; Kaji, R.; Kozaki, S.; Ginnaga, A. 2010: Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP) Toxicon: Official Journal of the International Society on Toxinology 55(2-3): 662-665
Ponmariappan, S.; Jain, S.; Sijoria, R.; Tomar, A.; Kumar, O. 2012: Expression, purification and development of neutralizing antibodies from synthetic BoNT/B LC and its application in detection of botulinum toxin serotype B Protein and Peptide Letters 19(3): 288-298